Totally agree malmanu, considering ovarian & AML trials have been given the green light to proceed with slight change in protocol, one would think similar logic will apply with the phase 2 breast trial. With all that is going on in current ptx200 trials plus kicking off ptx100 in heamotology niche, I'm anticipating an SP re-rate to Edison valuation of 0.29 + is very likely in 2018! See you at the AGM...
PTX Price at posting:
7.0¢ Sentiment: Buy Disclosure: Held
